<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579263</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-D1D2</org_study_id>
    <nct_id>NCT04579263</nct_id>
  </id_info>
  <brief_title>Assessment of the Health Improvement of Obese Patients After Fecal Microbiota Transplantation (FMT)</brief_title>
  <official_title>Assessment of Improvement in Glycemic Control, Weight, and Insulin Sensitivity in Obese Patients After Fecal Microbiota Transplantation (FMT) Against the Background of Glucose-lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research and Clinical Center of Physical-Chemical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endocrinology Research Centre, Moscow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research and Clinical Center of Physical-Chemical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Search for mechanisms of the effect of fecal microbiota transplantation on patients with&#xD;
      obesity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To select recipients of fecal samples according to eligibility criteria;&#xD;
&#xD;
        2. To perform fecal microbiota transplantation for patients with obesity;&#xD;
&#xD;
        3. To analyze the efficacy of fecal microbiota transplantation for patients with obesity&#xD;
           within six months after therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two obese patients selected according to the inclusion criteria will undergo fecal microbiota transplantation from a healthy donor with a normal body mass index against the background of glucose-lowering therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin sensitivity within FMT, 6 months after FMT]</measure>
    <time_frame>6 months after FMT</time_frame>
    <description>participants will undergo euglycaemic glucose clamp study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Obesity; Familial</condition>
  <arm_group>
    <arm_group_label>Patient with diabetes mellitus type 1 (T1DM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by transplantation of fecal microbiota</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with diabetes mellitus type 2 (T2DM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by transplantation of fecal microbiota</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiota</intervention_name>
    <description>Transplantation of fecal microbiota of healthy donor with normal body mass index</description>
    <arm_group_label>Patient with diabetes mellitus type 1 (T1DM)</arm_group_label>
    <arm_group_label>Patient with diabetes mellitus type 2 (T2DM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of patients - from 18 to 75 years, both sexes;&#xD;
&#xD;
          -  patients with obesity (body mass index â‰¥40&#xD;
&#xD;
          -  patient's informed consent to perform fecal microbiota transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of a concomitant chronic infectious disease or malignancy&#xD;
&#xD;
          -  patients with a proven allergy to foods not excluded from the donor's diet&#xD;
&#xD;
          -  absence of the patient for one or more intermediate stages of the examination.&#xD;
&#xD;
          -  informed refusal to continue therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Ilina, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Shestakova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Endocrinology Research Centre, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Zhgun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Pokrovskaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Research Centre, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Sklyanik</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Research Centre, Moscow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology Research Centre, Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow (FRCC PCM)</name>
      <address>
        <city>Moscow</city>
        <zip>117312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

